Wednesday 14 January 2026
  • About
  • Contact
  • Login
  • VC & Investment
  • M&A
  • AI
  • Podcasts
  • News
    • Pharmaceutical News
    • Biotechnology News
    • Generics News
    • Biosimilars news
    • In Brief
    • Legal
    • Company Pages
    • In The Boardroom
  • Insights
    • Analysis
    • Special Report
    • Interviews
    • Expert View
    • From Our Correspondent
    • One To Watch Companies
    • Digital Pharma
    • Pharma Leaders
  • Regulatory
    • FDA
    • EMA
    • Pricing, Reimbursement and Access
    • Regulation
    • Government Affairs
    • Trump Administration
  • Therapy Areas
    • Dermatologicals
    • Oncology
    • Neurological
    • Rare Diseases
    • Hematology
    • Cardio Vascular
    • Diabetes
    • Cell And Gene Therapy
  • Conferences
    • JPM Healthcare Conference
    • ESMO
    • ASCO
    • ASH
    • EULAR
    • AAIC
    • EASD
    • Forthcoming Events
  • Ones to Watch
  • About
  • Contact
  • Newsletter
  • Sign inSubscribe
Subscribe
  • Home
  • UPDATE: UK doctors warn on Internet drug sales: 25% have treated related adverse effects

UPDATE: UK doctors warn on Internet drug sales: 25% have treated related adverse effects

19 April 2009

Doctors in the UK have warned of the perils of buying medicines over the Internet. One in four general practitioners polled said they had treated  patients for adverse reactions to medicines bought on-line, according to  a report from public broadcaster the BBC.

A further 8% suspected they had treated side effects of Internet-bought  drugs, according to a snapshot survey of 423 doctors carried out by GP  Magazine, a UK publication for general practitioners.

Pharmacist leaders urged the public to be aware of the risks of Internet  medicines and use bone fide sites which require a prescription. Overall,  85% of the GP respondents want on-line pharmacies to be more tightly  regulated. However, no specific ideas were presented as to how this  might be accomplished, given how easy it is for a business to register a  web site outside UK jurisdiction.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Try before you buy

 

Free

7 day trial access

Take a Free Trial
  • All the news that moves the needle in pharma and biotech
  • Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
  • Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





More ones to watch >


Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news






Today's issue

First glimpse of new Novo Nordisk CEO’s strategy at JP Morgan
Pharmaceutical
First glimpse of new Novo Nordisk CEO’s strategy at JP Morgan
14 January 2026
Pharmaceutical
FDA grants Ipsen’s IPN60340 Breakthrough status
14 January 2026
Pharmaceutical
Merck sketches $70 billion post-Keytruda runway as 2028 looms
14 January 2026
Biotechnology
JPM: Almirall maps out a busy 2026 for dermatology R&D
14 January 2026
Pharmaceutical
FDA approves first treatment for children with Menkes disease
14 January 2026
Generics
Novo Nordisk trying to stop exports of Russian generic of Ozempic
14 January 2026
Pharmaceutical
Preparedness requires building countermeasures before crisis
14 January 2026

Company Spotlight

Nuclera
A life science tools company headquartered in Cambridge, UK, with operations in Boston, Massachusetts. The business sells and supports benchtop systems used by research organizations to accelerate access to functional proteins for drug discovery and protein engineering workflows.




The Pharma Letter

39-43 Putney High Street, Putney
London, SW15 1SP
United Kingdom

  • About us
  • Contact
  • Subscribe
  • Sponsorship/advertising


  • Terms and Conditions
  • Privacy Policy
  • Twitter
  • Linkedin

Copyright © The Pharma Letter 2025   |   Headless Content Management with Blaze